Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.69 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.63 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | SNCA | P37840 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4450332 | 1.00 | ABCG2 (0.69) | ABCG2NFE2L2TNFRSF1AAPPSNCA | |
| SCHEMBL19183469 | 0.91 | AURKA (0.66) | ABCG2NFE2L2APPSNCAAURKA | |
| SCHEMBL19183470 | 0.91 | AURKA (0.66) | ABCG2NFE2L2APPSNCAAURKA | |
| SCHEMBL15155231 | 0.84 | ABCG2 (0.68) | ABCG2NFE2L2TNFRSF1AAPPSNCA | |
| SCHEMBL15155236 | 0.84 | ABCG2 (0.68) | ABCG2NFE2L2TNFRSF1AAPPSNCA | |
| SCHEMBL19183189 | 0.81 | NFE2L2 (0.74) | ABCG2NFE2L2NPC1LMNABCHE | |
| SCHEMBL19183192 | 0.81 | NFE2L2 (0.74) | ABCG2NFE2L2NPC1LMNABCHE | |
| SCHEMBL7196216 | 0.80 | TNFRSF1A (0.59) | ABCG2NFE2L2TNFRSF1AAURKANPC1 | |
| SCHEMBL7196210 | 0.80 | TNFRSF1A (0.59) | ABCG2NFE2L2TNFRSF1AAURKANPC1 | |
| SCHEMBL979440 | 0.80 | ABCG2 (0.75) | ABCG2TNFRSF1AAURKANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | UNIVERSITE JOSEPH FOURIER GRENOBLE I (FR) | 2009-07-16 | — | — | US | claimed |
| EP-2810198-B1 | ANTI-INVASIVE COMPOUNDS | UNIV GENT (BE) | 2023-07-12 | — | — | EP | disclosed |
| US-9290427-B2 | Anti-invasive compounds | UNIVERSITEIT GENT (BE) | 2016-03-22 | — | — | US | disclosed |
| US-20150011620-A1 | ANTI-INVASIVE COMPOUNDS | UNIVERSITEIT GENT (BE) | 2015-01-08 | — | — | US | disclosed |
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | UNIVERSITE JOSEPH FOURIER GRENOBLE I (FR) | 2009-07-16 | — | — | US | disclosed |
| EP-1976818-A2 | CHALCONE DERIVATIVES WITH ANTIMITOTIC ACTIVITY | UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007083060-A2 | NOVEL CHALCONE DERIVATIVES WITH ANTIMITOTIC ACTIVITY | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011620-A1 | ANTI-INVASIVE COMPOUNDS | MMP3, MMP10, MIF | ABCG2 216/4885NFE2L2 1215/4885TNFRSF1A 2395/4885 |
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | ABCE1, CCNE1, FOXM1 | ABCG2 38/4885NFE2L2 234/4885TNFRSF1A 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.